SLC5A2 and metabolic dysfunction-associated steatotic liver disease: The E-LIFT trial showed [39] that SGLT-2 inhibitors can improve hepatic steatosis and fibrosis T2DM patients with NAFLD and reduce alanine aminotransferase (ALT) levels.